Anticancer Drug Development, System Updating and Global Participations
Background: New anticancer drug discovery, development and manufacture entered the bottleneck stage. Many limitations of both technology and animal models slow down the anticancer drug developments Objective: To ease economic burdens for drug developers and general patient populations. Methods: Key factors affecting anticancer drug developments and possible roadmaps for updating drug screening routines worldwide are suggested. Results: Drug development chains must be updated and better drug development paradigms must be established. Conclusions: This world welcomes global participations in anticancer drug developments and utilities..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2017 |
|---|---|
| Erschienen: |
2017 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Current drug therapy - 12(2017), 1, Seite 37-45 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Da-Yong Lu [VerfasserIn] |
|---|
| Links: |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
OLC1995566810 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | OLC1995566810 | ||
| 003 | DE-627 | ||
| 005 | 20230517050058.0 | ||
| 007 | tu | ||
| 008 | 170721s2017 xx ||||| 00| ||eng c | ||
| 028 | 5 | 2 | |a PQ20170901 |
| 035 | |a (DE-627)OLC1995566810 | ||
| 035 | |a (DE-599)GBVOLC1995566810 | ||
| 035 | |a (PRQ)benthamscience_primary_http_www_eurekaselect_com_openurl_content_php_genre_article_issn_1574_8855_volume_12_issue_1_spage_370 | ||
| 035 | |a (KEY)0598958220170000012000100037anticancerdrugdevelopmentsystemupdatingandglobalpa | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 540 |a 610 |q DE-600 |
| 084 | |a PHARM |2 fid | ||
| 100 | 0 | |a Da-Yong Lu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Anticancer Drug Development, System Updating and Global Participations |
| 264 | 1 | |c 2017 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 520 | |a Background: New anticancer drug discovery, development and manufacture entered the bottleneck stage. Many limitations of both technology and animal models slow down the anticancer drug developments Objective: To ease economic burdens for drug developers and general patient populations. Methods: Key factors affecting anticancer drug developments and possible roadmaps for updating drug screening routines worldwide are suggested. Results: Drug development chains must be updated and better drug development paradigms must be established. Conclusions: This world welcomes global participations in anticancer drug developments and utilities. | ||
| 700 | 0 | |a Ting-Ren Lu |4 oth | |
| 700 | 0 | |a En-Hong Chen |4 oth | |
| 700 | 0 | |a Nagendra Sastry Yarla |4 oth | |
| 700 | 0 | |a Bin Xu |4 oth | |
| 700 | 0 | |a Jian Ding |4 oth | |
| 700 | 0 | |a Hong Zhu |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug therapy |d [S.l.] : Bentham Science, 2006 |g 12(2017), 1, Seite 37-45 |w (DE-627)527561886 |w (DE-600)2274490-3 |w (DE-576)435514210 |x 1574-8855 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2017 |g number:1 |g pages:37-45 |
| 856 | 4 | 2 | |u http://www.eurekaselect.com/openurl/content.php?genre=article&issn=1574-8855&volume=12&issue=1&spage=37 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2017 |e 1 |h 37-45 | ||